Biocon Limited has notified stock exchanges regarding a name change of its step-down subsidiary in Ireland. The pharmaceutical company filed the intimation under Regulation 30 on March 30, 2026, addressing both BSE Limited and National Stock Exchange of India Limited.

Subsidiary Name Change Details

The company received information from Biocon Biologics Limited (BBL), one of its material subsidiaries, on March 29, 2026, regarding the corporate restructuring. The name change affects a subsidiary of BBL operating in Ireland.

Regulatory Compliance

The notification was submitted to comply with regulatory requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. The communication was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, who holds ICSI Membership Number A16328.

Corporate Structure

Biosimilar Collaborations Ireland Limited operates as a step-down subsidiary of Biocon Limited through Biocon Biologics Limited. BBL serves as one of the material subsidiaries within Biocon's corporate structure, focusing on the biologics business segment.

Information Accessibility

Biocon Limited has confirmed that the information regarding this subsidiary name change will be made available on the company's official website at www.biocon.com . This ensures transparency and easy access for stakeholders and investors seeking details about the corporate restructuring.

Biocon Limited has informed stock exchanges about the submission of Amendment #7 to the Biocon India Limited Employees Welfare Trust deed, in compliance with Regulation 3(3) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The amendment was executed on March 27, 2026, and involves significant changes to the Trust's governance structure.

Trustee Resignations and Appointments

The amendment outlines a complete restructuring of the Trust's Board of Trustees. In accordance with Article 13 of the Trust Deed, two existing trustees will step down from their positions:

Simultaneously, two new trustees have been appointed by mutual consent of the Settlor and the new trustees, as per Article 11 of the Trust Deed:

Trust Deed Modifications

The amendment represents the seventh modification to the original Trust Deed dated May 18, 2001. Previous amendments were executed on July 11, 2014, July 20, 2015, February 01, 2021, August 02, 2021, March 31, 2023, and October 09, 2025. The current amendment specifically modifies Article 8 of the trust deed to reflect the new Board composition.

New Board Composition

Effective April 01, 2026, the Board of Trustees will consist exclusively of the two newly appointed members:

• Mr. Mukesh Kamath
• Mr. Naveen Narayanan

Regulatory Compliance

The company has submitted the amendment deed to both BSE Limited and National Stock Exchange of India Limited through a formal communication dated March 27, 2026. The submission was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, ensuring adherence to regulatory requirements under SEBI guidelines for share-based employee benefits schemes.

The amendment deed has been duly executed with signatures from Kiran Mazumdar-Shaw as the Settlor, the outgoing trustees, and witnesses, completing all necessary legal formalities for the trustee transition.